In this article, we will look at the 14 Best 52-Week High Stocks To Buy According to Analysts.
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in. Pullbacks in various sectors have come into play amid growing concerns about overstretched valuations. Likewise, the pullbacks have come on bond yields surging to levels not seen in two months, triggering a selloff in growth-oriented stocks.
The 10-year yield touching highs of 4.79% has once again triggered demand for bonds at the expense of stocks, given the yields on offer. Additionally, the surge in bond yields comes on stronger-than-expected jobs reports that cast doubt on further interest rate cuts. The stock market rallied to record highs last year amid expectations that the Fed will embark on an aggressive easing push that involves interest rate cuts.
A spike in inflation levels amid a resilient US job market has once again averted the prospects of the Fed aggressively cutting interest rates. Consequently, the global rise in bond yields around the globe is being driven by expectations of fewer than expected interest rate cuts.
READ ALSO: 10 Best Blue Chip Stocks to Buy for 2025 and Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025.
“With the 10-year yield potentially getting to 5%, I think it’s going to be very hard for the equity market to really gain any meaningful traction here until there’s — at minimum — stability in interest rates,” said Adam Turnquist, chief technical strategist at LPL Financial.
The sentiments echo serious concerns about stocks trading at 52-week highs after blockbuster moves last year. Given that valuations at 52-week highs often appear overstretched, there are growing concerns that some of the stocks could be the subject of significant pullbacks. Amid the concerns, Turnquist does not see the prospect of the market edging into bear territory even though the market appears to be in a correction phase.
Analysts at Goldman Sachs are also bullish about the equity market’s outlook and believe there is not enough reason to back away from investing. Additionally, the analysts don’t expect 2025 to be a problematic year for equity investments.
“Valuations are not a good timing signal. … There’s no clear relationship between your starting valuation and the returns one year later,” Brett Nelson, head of tactical asset allocation for the group, said
Goldman Sachs analysts expect the US economy to grow faster than Europe in 2025. A resilient US economy amid high interest rates should fuel stellar financial results characterized by revenue and earnings growth.
“We do think that the earnings advantage that the U.S. has will continue,” said Sharmin Mossavar-Rahmani, chief investment officer for the Goldman unit.
The prospect of the US economy staying clear of recession even with the Fed leaving interest rates at current levels should offer much-needed support to stocks trading at all-time highs. Analysts also expect friendly regulations and deregulation from the upcoming Republican administration to act as a tailwind to fuel further gains in the equity markets.
A financial advisor with a client discussing the merits of a mutual fund, showing the company’s experienced advice in asset management.
Our Methodology
To make the list of best 52-week high stocks to buy according to analysts, we scanned various screeners focusing on stocks trading close to their 52-week highs. We then settled on stocks trading close to 52-week highs (0-10% below high), which analysts believe boast of 25% or more upside potential as of January 14, owing to their solid underlying fundamentals. Finally, we ranked the stocks in ascending order based on their upside potential.
At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
14 Best 52-Week High Stocks To Buy According to Analysts
14. NextDecade Corporation (NASDAQ:NEXT)
52 Week Range: $4.27 – $8.52
Current Share Price: $8.05
Stock Upside Potential: 24.22%
Number of Hedge Fund Holders: 21
NextDecade Corporation (NASDAQ:NEXT) is an energy company that engages in construction and development activities related to natural gas liquefaction. It focuses on the Rio Grande LNG terminal facility’s development activities in the Port of Brownsville in southern Texas. After rallying by about 73% in 2024, it is emerging as one of the best 52-week high stocks to buy, according to analysts.
NextDecade Corporation (NASDAQ:NEXT) has already inked a strategic agreement with Bechtel Energy for the construction of Phase 1 at the Rio Grande facility. The company holds equity interest in the Phase 1 joint venture that entitles it to receive up to 20.8% of distributions of available cash during operations. NEXT has also secured a $175 million senior loan that it plans to use to strengthen its financial position by paying existing debts.
Additionally, the funding will be useful in financing working capital and the development of expansion trains 4 and 5 at the Rio Grande LNG facility. Given the current state of the global energy transition, this development timing aligns with market opportunities. The structured financing demonstrates the market’s faith in NextDecade Corporation’s (NASDAQ:NEXT) LNG infrastructure. Significant capacity growth potential is represented by the extension of trains 4 and 5, which is crucial for economies of scale.
13. AXIS Capital Holdings Limited (NYSE:AXS)
52 Week Range: $53.97 – $94.89
Current Share Price: $87.82
Stock Upside Potential: 25.62%
Number of Hedge Fund Holders: 34
AXIS Capital Holdings Limited (NYSE:AXS) is a financial services company that provides various specialty insurance and reinsurance products. It offers professional insurance products that cover officers’ liability, errors and omissions, employment practices, medical malpractice, and other financial insurance. The company outperformed its peers significantly in 2024, delivering a 62% return, affirming why it is one of the best 52-week highs stocks to buy, according to analysts.
Throughout 2024, AXIS Capital Holdings Limited (NYSE:AXS) has proactively improved its primary casualty portfolio, anticipating stronger growth in 2025. This growth is supported by strategic changes and a consistent rise in casualty rates despite slower growth in the property segment. Additionally, AXIS Capital focuses on growth areas like lower middle markets and wholesale insurance to become a top specialty underwriter with a diverse portfolio, leadership roles, and expansion prospects positioning its insurance segment for success.
Strategic initiatives have been driving improvement in its operating earnings over the past few years. Reaching a general and administrative ratio of less than 11% by 2026 should be possible with the help of streamlining the operating structure, delivering efficiencies, and leveraging productivity gains. AXIS Capital Holdings Limited (NYSE:AXS) has a strong dividend history. It has increased its dividend for 18 years in a row and now yields 1.9%.
12. Dolby Laboratories, Inc. (NYSE:DLB)
52 Week Range: $66.35 – $86.37
Current Share Price: $79.20
Stock Upside Potential: 25.85%
Number of Hedge Fund Holders: 20
Dolby Laboratories, Inc. (NYSE:DLB) is an industrial company that creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services. While the stock was down by about 7% in 2024, it remains one of the best 52-week high stocks to buy, according to analysts.
That’s partly due to a solid financial position that affirms underlying growth. Revenue in its fiscal fourth quarter totaled $305 million compared to $291 million a year before. Net income surged to $59 million compared to $9 million a year ago. Dolby Laboratories, Inc. (NYSE:DLB) expects better-than-expected financial results to persist in 2025, owing to strong momentum in its Dolby Atmos and Dolby Vision units.
Dolby Laboratories bolstered its imaging patent portfolio by acquiring GE Licensing, the intellectual property licensing division of General Electric Company (NYSE:GE), for $429 million. This strategic acquisition, funded by Dolby’s cash reserves, is expected to enhance its market position by integrating GE’s consumer electronics intellectual property into its products. With a positive outlook for growth in the automotive sector and increasing installations globally, Dolby Laboratories, Inc. (NYSE:DLB) continues to see significant engagement and growth from its Dolby Atmos and Dolby Vision technologies.
11. Delta Air Lines, Inc. (NYSE:DAL)
52 Week Range: $36.69 – $68.99
Current Share Price: $66.29
Stock Upside Potential: 26.22%
Number of Hedge Fund Holders: 57
Delta Air Lines, Inc. (NYSE:DAL) provides scheduled air transportation for passengers and cargo across the globe. While the stock was up by about 77% in 2024, there is still room to run, given the solid underlying fundamentals. The company enjoys strong demand trends in its passenger and cargo origination businesses as consumers prioritize spending on experiences.
Delta Air Lines, Inc. (NYSE:DAL) delivered better-than-expected fourth-quarter results on January 10, attributed to strong demand for travel, which is expected to continue in the New Year. Operating revenue in the quarter totaled $15.6 billion, leading to $843 million in net income. Revenue for the full year totaled $61.6 billion, leading to adjusted earnings per share of $6.16.
Delta Air Lines, Inc. (NYSE:DAL) expects a continuation of strong demand trends, which explains why it is one of the best 52-week high stocks to buy, according to analysts. The airline expects revenue in 2025 to increase by between 7% and 9%. It also expects low single-digit growth in Cost per available seat mile. The projections are based on the airline’s expected efficiencies and ongoing workforce and customer experience investments.
10. EZCORP, Inc. (NASDAQ:EZPW)
52 Week Range: $8.20 – $12.85
Current Share Price: $12.13
Stock Upside Potential: 30.37%
Number of Hedge Fund Holders: 21
EZCORP, Inc. (NASDAQ:EZPW) is a financial services company that provides pawn services. It offers pawn loans collateralized by tangible personal property, jewelry, consumer electronics, tools, sporting goods, and musical instruments. The impressive run to a 52-week high came on the company delivering record-breaking financial results that underscore growth in the core business.
The pawn services company delivered an 11% year-over-year increase in fourth-quarter revenue to $330.9 million. Pawn loan originations were also up by 14% to $279.2 million. The robust sales growth comes from EZCORP pursuing strategic initiatives and expansion, including adding 21 new stores.EZCORP, Inc.’s (NASDAQ:EZPW) impressive Q4 results and strong loan and sales growth in every region point to a bright future for EZCORP, even though some regions saw a slight slowdown after the disruption.
Last year, EZCORP, Inc. (NASDAQ:EZPW) reached an agreement to acquire 53 pawn stores in Mexico. The acquisition is a part of the company’s expansion plan as it continues to diversify its revenue base. Additionally, it is opening up new business opportunities in pursuit of new growth opportunities.
9. Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
52 Week Range: $3.03 – $15.00
Current Share Price: $13.42
Stock Upside Potential: 31.77%
Number of Hedge Fund Holders: 8
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a specialty pharmaceutical company that develops, acquires, and commercializes pharmaceutical products for rare diseases. It offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency. The stock exploded in 2024, rallying by 228%. The rally to 52-week highs came as the market reacted to an aggressive acquisition drive as the company continued to strengthen its product portfolio.
In addition, the stock has been trading higher owing to stellar financial results. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) delivered a 15th consecutive quarter of revenue growth, with product sales increasing by 40% in the third quarter to $9.8 million. Eton has also moved to strengthen its revenue base with plans to acquire 10 commercial products with the prospects of generating $100 million in revenue in the rare disease portfolio.
As part of its acquisition drive, Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has agreed to acquire US rights to Amglidia, a treatment developed for neonatal diabetes mellitus. The acquisition aligns with the company’s bid to strengthen paediatric endocrinology. In addition, it has completed the asset purchase of Increlex®, a biologic product used to treat pediatric patients 2 years of age and older struggling with insulin-like growth factor 1 deficiency (SPIGFD). ETON also plans to start commercializing Galzin, an FDA-approved maintenance treatment for patients with Wilson’s disease who have been initially treated with a chelating agent, as it looks to strengthen its revenue streams.
8. SunOpta Inc. (NASDAQ:STKL)
52 Week Range: $4.88 – $8.11
Current Share Price: $7.34
Stock Upside Potential: 40.11%
Number of Hedge Fund Holders: 18
SunOpta Inc. (NASDAQ:STKL) engages in the manufacture and sale of plant-based and fruit-based food and beverage products. It provides plant-based beverages utilizing oats, almonds, soy, coconut, and rice. The stock was on a roll, rallying by 30% in 2024. The rally came after the company announced plans to expand its Dream Oatmilk Barista product distribution to 6,700 locations across North America.
Reports suggest that SunOpta Inc. (NASDAQ:STKL) could be in partnership with Starbucks as part of the expansion drive in North America is another catalyst that should strengthen growth metrics. Likewise, the distribution deal is expected to take advantage of the company’s existing manufacturing infrastructure, including its Modesto facility in California. The expanded reach of the Oatmilk products should support the company’s financial trajectory.
SunOpta Inc.’s (NASDAQ:STKL) business development pipeline has been a key driver of its 2024 performance, and this expansion confirms its efficacy. Second, as the advantages of the wider distribution materialize, it is anticipated to boost investor confidence for the fiscal year 2025. The expansion drive should strengthen the company’s revenue base, driven by 20% volume growth.
7. Royalty Pharma plc (NASDAQ:RPRX)
52 Week Range: $24.05 – $31.66
Current Share Price: $30.03
Stock Upside Potential: 45.33%
Number of Hedge Fund Holders: 33
Royalty Pharma plc (NASDAQ:RPRX) is a healthcare company that operates as a buyer of biopharmaceutical royalties and a financier of innovations in the biopharmaceutical industry. It is also involved in identifying, evaluating, and acquiring royalties on various bio-pharmaceutical therapies. After rallying by about 5% in 2024, the stock has started 2025 on a roll, rallying by about 17%.
According to analysts, amid the strong moves in the market, Royalty Pharma plc (NASDAQ:RPRX) is one of the best 52-week high stocks to buy. That’s partly due to the key achievements clocked in 2024, including about $2.8 billion in portfolio receipts. The company also achieved a 13% growth in royalty receipts. A confirmation that the company is on course to acquire its external manager, RP Management, for $1.1 billion, saving it more than $1.6 billion in ten years, should allow it to generate more shareholder value.
A resilient evaluation and acquisition of royalties has allowed Royalty Pharma plc (NASDAQ:RPRX) to generate significant cash flow to return value to shareholders. The stock continues to reward investors with a 2.93% dividend yield, having increased its quarterly payout by 5% to $0.22 a share.
6. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
52 Week Range: $99.06 – $134.17
Current Share Price: $122.96
Stock Upside Potential: 46.09%
Number of Hedge Fund Holders: 40
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biotechnology company that identifies, develops, and commercializes pharmaceutical products for unmet medical needs. It offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy. It is one of the best 52-week high stocks to buy, according to analysts, as it is making impressive strides in the oncology space.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is working on a promising oncology drug, zanidatamab, as a potential treatment for HER2-resistant cancers. The lead candidate drug has the potential to become a first-line treatment option. If approved, the drug would help strengthen the company’s pipeline, which currently consists of Xywav and Epidiolex/Epidyolex.
Xywav and Epidiolex/Epidyolex are currently driving Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) top line, having achieved double-digit percentage growth to over $1 billion in sales last year. The company is also pursuing growth opportunities in the cannabis sector, and its sales have increased by 18% in the third quarter to $251 million.
5. Riley Exploration Permian Inc (NYSE:REPX)
52 Week Range: $21.27 -$ 37.15
Current Share Price: $35.31
Stock Upside Potential: 50.36%
Number of Hedge Fund Holders: 11
Riley Exploration Permian, Inc. (NYSE:REPX) is an independent oil and natural gas company that engages in acquiring, developing, and producing oil, natural gas, and natural gas liquids. It was one of the best-performing energy stocks rallying by 55% in 2024 even as the overall sector came under pressure with oil prices plunging below $70 a barrel.
The stock’s rally to 52-week highs came on Riley Exploration delivering solid financial results in a challenging market environment characterized by depressed oil prices. Revenue in the quarter totaled $102.34 million, slightly below the $108.29 million a year ago, beating estimates by 0.67%. Operating cash flow improved quarter over quarter to $72.1 million despite lower oil prices and was driven by higher production and improved commodity hedge settlements.
Riley Exploration Permian, Inc.’s (NYSE:REPX) anticipated 14% to 15% annual growth in oil production for 2024 demonstrates its dedication to long-term value creation and operational excellence. Infrastructure investment and organic development are anticipated to be the primary drivers of this growth. Riley Exploration also generated $99 million in free cash flow, of which $70 million was used for debt reduction and $23 million for dividend payments.
4. Net Lease Office Properties (NYSE:NLOP)
52 Week Range: $22.16 – $33.06
Current Share Price: $31.58
Stock Upside Potential: 52.82%
Number of Hedge Fund Holders: 17
Net Lease Office Properties (NYSE:NLOP) operates as a real estate investment trust with 59 high-quality office properties totaling approximately 8.7 million leasable square feet. As of the end of 2024, the company had about 39 office properties. The ability of the stock to outperform the overall market with a 30% rally in 2024 in a challenging high interest rate environment affirms the resilience of the core business.
While Net Lease Office Properties (NYSE:NLOP) is trading near an all-time high, it remains one of the best 52-week high stocks to buy, according to analysts. That’s because strategic initiatives and market positions are increasingly paying off at a time when the FED is cutting interest rates. A reduction in interest rates is causing mortgage rates to decrease, consequently triggering demand for real estate deals.
As 2024 came to a close, Net Lease Office Properties (NYSE:NLOP) completed the sale of five office properties for total gross proceeds of $43.3 million. The sale allowed the company to raise significant free cash flow to pay off $30 million of JPMorgan’s mortgage. The company’s total disposition for 2024 stood at $364 million.
3. Telephone and Data Systems Inc. (NYSE:TDS)
52 Week Range: $13.69 – $35.39
Current Share Price: $34.33
Stock Upside Potential: 57.62%
Number of Hedge Fund Holders: 31
Telephone and Data Systems Inc. (NYSE:TDS) is a communication services company that offers wireless solutions to consumers, business and government customers. It offers a suite of connected Internet of Things (IoT) solutions and software applications. The stock soared to 52-week highs in 2024 after rallying by about 81%. The rally to record highs came as Wall Street reacted to strong growth in the company’s residential broadband connections and healthy tractions in its fixed wireless portfolio.
Fibre networks across total service addresses stood at 49% in the third quarter and are on course to reach 60% owing to strong demand. Likewise, Telephone and Data Systems Inc.’s (NYSE:TDS) residential broadband connections reached 115,300, up from 79,400 a year ago. Telephone and Data Systems is already reaping the benefits of fiber broadband investment made in the past couple of years, which is boosting revenues and profitability.
Management focusing on cost optimization to drive profitability has also helped bolster the stock’s sentiments. Alongside these advancements, TDS US Cellular is working to reach 1.2 million marketable fiber addresses by growing its fiber network. Along with a national 5G partner, Telephone and Data Systems Inc. (NYSE:TDS) is getting ready to launch an MVNO.
2. Delcath Systems, Inc. (NASDAQ:DCTH)
52 Week Range: $3.70 – $13.30
Current Share Price: $12.69
Stock Upside Potential: 73.32%
Number of Hedge Fund Holders: 17
Delcath Systems, Inc. (NASDAQ:DCTH) is an interventional oncology company that focuses on the treatment of primary and metastatic liver cancers. The company’s lead product candidate is HEPZATO KIT, designed to administer high-dose chemotherapy to the liver. After rallying by more than 200% in 2024, the stock has started 2025 on a roll and trading close to its 52-week highs.
Delcath Systems, Inc. (NASDAQ:DCTH) remains one of the best 52-week high stocks to buy, according to analysts, on the back of solid financial results characterized by record sales in recent quarters. The record sales come on strong adoption of the company’s HEPZATO kit, affirming growing market acceptance of the product.
Delcath Systems, Inc. (NASDAQ:DCTH) is projecting revenues of $15.1 million for its fourth quarter against $12.4 million, which analysts expect will continue to strengthen its sentiments in the market. The specialty pharmaceutical company also projects full-year sales of $37.2 million against the expected $34.5 million. The better-than-expected sales numbers affirm that Delcath Systems expects continued growth and strong market position in 2025 as in 2024. The success of the HEPZATO launch and the sequential revenue growth demonstrate strong market adoption. According to the product mix, HEPZATO generates 87% of total revenues and CHEMOSAT 13%, demonstrating successful market penetration in the US.
1. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
52 Week Range: $15.19 – $27.29
Current Share Price: $23.67
Stock Upside Potential: 78.08%
Number of Hedge Fund Holders: 29
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a late-stage biopharmaceutical company that develops therapies to enhance patient care in populations with metabolic diseases. It is developing anacetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor. The stock has been flying high and remains one of the best 52-week high stocks to buy, according to analysts, owing to a string of positive news on the development of its pipeline of drugs.
In 2024, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced that three Phase 3 trials of its lead products had produced favorable topline results. TANDEM achieved 49% LDL-C reduction with fixed-dose combination; BROOKLYN showed 36% LDL-C reduction; and BROADWAY showed 33% LDL-C reduction and 21% MACE reduction. NewAmsterdam Pharma exited 2024 with $835 million in the balance sheet, sufficient to accelerate the development of the three programs.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is gearing up for significant commercial demand through its manufacturing scale-up and inventory build-out strategy. A European commercialization partnership with Menarini further validates its efforts and enhances income potential. The company is optimistic about Obicetrapib’s long-term prospects, having secured patent protection until 2043. Currently, it is focusing on commercial readiness by establishing manufacturing capacity, which strengthens its intellectual property portfolio and long-term revenue potential.
While we acknowledge the growth potential of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NAMS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
